Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chongqing Precision Biological Industrial Technology Research Institute Co. Ltd. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action recorded for this portfolio. This indicates a concentrated prosecution phase, where the company is focusing its resources on a specific pharmaceutical or biotechnological advancement.
The portfolio's active matters are handled by 1 distinct examiner and 1 distinct art unit. This suggests that the technology being patented is highly specialized, requiring review by a specific examination group. The absence of multiple examiners or units means that the prosecution strategy is not fragmented across different parts of the patent office.
CHATTIN, AMY MARIE is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner is responsible for all current pending matters. The focus on 1 distinct art unit and 1 distinct examiner ensures that the company's current patent prosecution is centralized and consistent.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHATTIN, AMY MARIE | 1 | 73.6% | +44.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17926790 | FUSION PROTEIN FOR REVERSING TUMOR MICROENVIRONMENT AND USE THEREOF | CHATTIN, AMY MARIE | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17926790 | FUSION PROTEIN FOR REVERSING TUMOR MICROENVIRONMENT AND USE THEREOF | CHATTIN, AMY MARIE | 1643 | §103 | Non-Final OA | 46d overdue | Pending | Nov 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial